BALTIMORE, Md., April 25, 2019 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocytes (MILs™) for cancer immunotherapy, has announced the appointment of Donald J. Hayden, Jr., as CEO. Mr. Hayden currently serves as interim CEO and Chairman of the Board.
“We are extremely pleased that Don has accepted the role of WindMIL CEO,” said Mark McDade, Managing Partner of Qiming Venture Partners USA and Board member at WindMIL. “Don brings a wealth of experience to the position from his impressive 25-year career at Bristol-Myers Squibb Company and many years helping build successful emerging biotech companies. His knowledge of the life sciences industry is unparalleled, and he has a compelling vision for developing MILs to their full potential to save lives. We are excited by WindMIL’s future prospects under Don’s leadership.”
The CEO role at WindMIL is the first full-time executive position Mr. Hayden has accepted since his time at Bristol-Myers Squibb, where he served as president of Global Pharmaceuticals; executive vice president and president, Americas; executive vice president of the Health Care Group and president of Oncology and Immunology. Since leaving Bristol-Myers Squibb, he has served as chairman of numerous biotech company boards, including REGENXBIO, Amicus Therapeutics, Insmed, Vitae Pharmaceuticals and Gloucester Pharmaceuticals.
“I am very excited to assume this broader leadership role at WindMIL,” said Mr. Hayden, who will continue to serve as the Chairman of WindMIL’s Board of Directors. “During my time chairing the company’s board and more recently as the interim CEO, I’ve gotten an ever-closer look at MILs’ impressive potential to improve the treatment of both hematologic and solid tumors, and I look forward to working closely with the outstanding WindMIL team to bring the benefits of MILs to patients as quickly as possible.”
Mr. Hayden will be based primarily in WindMIL’s Philadelphia office, where the company’s clinical, business operations and finance functions are located, but he will also spend a significant portion of his time with the company’s research and process science teams, which are based in its Baltimore location.
About WindMIL Therapeutics
WindMIL Therapeutics is a clinical-stage company developing a novel class of autologous cell therapies based on marrow infiltrating lymphocytes (MILs™) for cancer immunotherapy. As the leader in cellular therapeutics emanating from bone marrow, WindMIL translates novel insights in bone marrow immunology into life-saving cancer immunotherapeutics for patients. The company’s proprietary process to extract, activate and expand these cells offers unique immunotherapeutic advantages, including inherent tumor-specificity, high cytotoxic potential, and long persistence. For more information, please visit: https://windmiltherapeutics.com.
Media Contact:
Tony Plohoros
6 Degrees
(908) 940-0135
tplohoros@6degreespr.com
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/bb6c3f80-0258-4b71-b4fb-ae9f4012ae81